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Abstract
Introduction: Tumour phenotype is regulated in a complex fashion as a result of interactions between malignant
cells and the tumour stroma. Fibroblasts are the most abundant and perhaps most active part of the tumour
stroma. A better understanding of the changes that occur in fibroblasts in response to the presence of malignant
cells may lead to the development of new strategies for cancer treatment. We explored the effects of fibroblasts
on the growth and invasion of mammary carcinoma tumour cells in vitro and in vivo.
Methods: In order to analyse secreted factors that affect invasive abilities of breast cancer cells we co-cultured
human mammary fibroblasts (HMF3s) and cancer cells (MCF7S1) in three-dimensional (3D) growth conditions
devoid of heterogeneous cell-cell contact. To study the possible influence of fibroblasts on MCF7S1 cancer cell
growth in vivo we co-injected HMF3s and MCF7S1 cells in Balb/c nu/nu mice.
Results: In 3D co-culture both HMF3s and MCF7S1 cells demonstrated enhanced invasion into a Matrigel matrix.
This was correlated with enhanced expression of the metastasis promoting S100A4 protein in fibroblasts,
stimulation of the matrix metalloproteinase (MMP)-2 activity, and enhanced secretion of a range of different
cytokines. Orthotopic injection of oestrogen-dependent MCF7S1 cancer cells together with fibroblasts showed
stimulation of tumour growth in mice without an external oestrogen supply. The resulting tumours were
characterized by increased development of extracellular matrix, as well as an increase of murine S100A4
concentration and activity of MMP-2 in the tumour interstitial fluid.
Conclusion: Stimulation of the invasive phenotype of tumour cells in 3D co-cultures with fibroblasts could be
correlated with increased production of S100A4 and MMP-2. We propose that enhanced development of mouse
host-derived tumour stroma in a MCF7S1 co-injection xenograft model leads to oestrogen independency and is
triggered by the initial presence of human fibroblasts.
Background
In most human tumours, the stroma microenvironment
is heavily altered compared with the stroma of normal
tissue [1]. Both the composition of the extracellular
matrix (ECM) and the ratio between the different cell
types present in the microenvironment are different in
normal compared with activated stroma [2]. Stroma
cells are now well known to play a pivotal role in pro-
moting tumour growth [3,4]. The general consensus is
that the stroma triggers neoplastic progression through
signals within the stroma environment (reviewed in
[5,6]).
The stroma closely associated with benign as well as
malignant epithelia consists of ECM and cellular com-
ponents, including fibroblasts, adipocytes, endothelial
and immune cells, all of which have the potential to
influence progression of tumour cells toward a more
aggressive state [5,7]. Fibroblasts are the most studied
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has been repeatedly proven [8].
Progression of breast cancer is accompanied with
alterations in gene expression both in epithelial cancer
cells and cells composing tumour stroma [9]. Alterations
in gene expression are at least in part determined by
soluble factors produced into the tumour microenviron-
ment both by tumour cells and stroma fibroblasts [10].
Several molecules produced by the stroma cells into
the tumour microenvironment are known to stimulate
tumour progression. Among these are MMPs [11], dif-
ferent cytokines [12] and the metastasis-associated pro-
tein S100A4 [13].
A large number of models have been proposed to
study the tumour microenvironment, and significant
developments have occurred in the complexity of these
models making them more comparable to the in vivo
models [14,15]. The most commonly used 3D models
for include spontaneous cell aggregation, liquid overlay
cultures, spinner flask spheroid cultures, and various
scaffold-based cultures [16].
T os t u d yt h ee f f e c t so fs t r o m ac o m p o n e n t so n
tumourigenesis various co-culture models involving
benign or cancer cells and mostly fibroblasts have been
implemented. Krause and colleagues co-cultured the
benign breast epithelial MCF10-A cell line with normal
mammary fibroblasts to study the importance of stroma
in mammary gland development and observed the for-
mation of ductal as well as alveolar structures, both
resembling those found in vivo [17]. Sadlonova and col-
leagues used a three-dimensional (3D) co-culture model
with epithelial cancer cells and primary fibroblasts and
discovered that normal mammary gland-associated
fibroblasts were able to inhibit tumour cell proliferation,
whereas carcinoma-associated fibroblasts tended to sti-
mulate their growth [18].
In this study using a 3D co-culture system we
attempted to identify a panel of soluble factors produced
by fibroblasts that stimulate invasion of tumour cells.
We also attempted to compare the response of tumour
cells to fibroblasts using model systems of different
levels of complexity: co-cultured in 2D or 3D in-vitro,
or grafted to the mammary fat pad of immunodeficient
mice.
Methods
Cell lines and growth conditions
The BJ fibroblast cell line (established from normal
human foreskin) was obtained from the American Type
Culture Collection (Rockville, MD, USA). The HMF3s
fibroblast cell line, established from healthy mammary
tissue [19], was a gift from Professor Mike O’Hare (Lud-
wig Institute, London, UK). The breast cancer cell lines
MCF7 and MCF7S1 (a highly tumour-necrosis factor
(TNF)-a s e n s i t i v ed e r i v a t i v eo fM C F 7 ) ,w e r eg i f t sf r o m
Marja Jäättela (Apoptosis Laboratory, Danish Cancer
Society, Denmark) [20].
All cell lines were grown in Dulbecco’sM o d i f i e d
Eagle’s Medium (DMEM) supplemented with 10% fetal
calf serum (FCS), penicillin (200 U/ml), and streptomy-
cin sulphate (100 U/ml) in a humidified incubator sup-
plied with 5% CO2. Conditioned media (CM) were
produced by growing an appropriate cell line in a T75
f l a s ki n1 5m lo ff r e s hg r o w t hm e d i af o r4 8hf o l l o w e d
by sterile filtration (0.45 μm filter). Cells treated with
CM were analysed after 48 h of culturing and were sub-
sequently collected for Western blot analysis using lysis
buffer (50 nM Tris-Cl, pH 6.8, 2% sodium dodecyl
sulphate [SDS], 0.1% bromophenol blue, 10% glycerol,
and 100 mM dithiothreitol). Cell lysate samples for
Western analysis were normalised to the total protein
content determined by scanning of a Coomassie brilliant
blue R-250 stained SDS-PAGE gels. The treatment of
cells with CM was repeated four times.
Measurement of cell length and scattering
The length of fibroblasts treated with standard growth
media or tumour cell CM was determined by manual
measurement in the Fujifilm MultiGauge software allow-
ing for measurement of irregular shaped cell lengths.
The proportion of scattered tumour cells in the popu-
lations treated with DMEM or fibroblast CM was deter-
mined by manual classification. Tumour cells were
classified as scattered when a visual absence of cell-cell
contact was observed.
6 randomly selected fields at 100× magnification were
selected for analysis for each cell type in all setups. Each
field contained in average 60 fibroblasts or 530 tumour
cells to be included in the analysis.
Mice for in vivo experiments
Intact female Balb/c nu/nu mice were injected with 4 ×
10
6 cells per cell line in the R2 mammary fat. 10 animals
were used per group and selected groups were supplied
with oestrogen in the drinking water 6 days prior to the
injection of cells (0.67 μg/ml). This was continued for
the entire experiment. Tumours were manually mea-
sured throughout the experiment in two dimensions,
and the volume was calculated using the ellipsoid for-
mula: volume = 1/2 * a * b
2 (a = length, b = width) [21].
Animals were sacrificed at a sign of illness or after 100
days at termination of the experiment. All animal
experiments were approved by the Animal Welfare
Inspectorate at the Danish Ministry of Justice (ref. 2007/
561-1395).
All animals with a palpable mass that upon histologi-
cal examination of random tumour sections did not
contain cancer cells were discarded from the analysis
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tory response to the injection.
Tumour interstitial fluid (TIF) analysis
TIFs were produced by cutting the tumours into smaller
1 mm-sized pieces followed by 2 h incubation at 37°C
in phosphate-buffered saline (PBS; 1:20 w/v ratio) as ori-
ginally described by Celis et al., 2004 [22]. Prior to ana-
lysis, the samples were normalized to the total protein
content measured by OD280.
Immunofluorescent cytostaining
Cells were fixed for 20 min in 4% paraformaldehyde fol-
lowed by membrane permeabilisation with 0.2% Triton X-
100 for 2 min. The following primary antibodies were incu-
bated for 1 h at RT: Vimentin (NeoMarker clone Ab-2,
1:1000 dilution), S100A4 (isolated as described in [23],
1:1500 dilution), oestrogen receptor (ER; NeoMarker clone
SP1, 1:500 dilution), E-cadherin (Abcam clone decma-1,
1:800 dilution), and pan-cytokeratins (DAKO #Z0622,
1:500 dilution). Alexa Fluor 488 goat anti-rabbit and Alexa
Fluor 568 goat anti-mouse were used as secondary antibo-
dies (1:1000 dilution for 1 h incubation at RT). Cells were
nuclear stained with 4’,6-diamidino-2-phenylindole (DAPI)
following mounting with ProLong® Gold antifading media
(Invitrogen). Fluorescent images were acquired with a
Zeiss AxioImager confocal microscope, and photographs
were processed using Zeiss Zen2008 software.
Immunohistochemical analysis of mouse tissue
Formalin-fixed paraffin-embedded tissue sections were
immunostained ON with the following antibodies: ER
(NeoMarker clone SP1, 1:500 dilution), progesterone
receptor (PgR) (NeoMarker clone SP2, 1:500 dilution),
Laminin (Sigma #L-0303, 1:200 dilution), Fibronectin
(NeoMarker #RB-077-A0, 1:500 dilution), S100A4 pAb
[23] 1:2000 dilution, F4/80 (Accurate Chemicals clone
A3-1, 1:2000 dilution) and prolyl-4-hydroxylase (DAKO
#M0877, 1:400 dilutions). Immunostaining was per-
formed according to the protocol of the manufacturer.
The EnVision
+ horseradish peroxidase (HRP)-labeled
detection system (DAKO) was utilized as the detection
system. For staining with F4/80 antibody, the tyramide
signal amplification biotin system was used for detection
(PerkinElmer). All slides were counterstained with
Mayers hematoxylin.
In order to quantify the proportion of PgR positive
cells, 10 random fields at 200× magnification per section
were analysed resulting in classification of 1500 cells per
tumour in average.
3D invasion assay
The experimental setup for this assay is described in
detail in Ambartsumian et al., 2006 [24]. Briefly, cells
were incubated overnight to form clumps on an inverted
lid in hanging droplets containing 4 × 10
4 or 6.5 × 10
4
cells (fibroblasts and cancer cells, respectively) suspended
in normal growth media. The formed cell aggregates
were manually transferred to a layer of polymerized
Matrigel™ (growth factor-reduced, BD) mixed 1:1 with
serum-free DMEM prior to use. The aggregate was cov-
ered with a sealing layer of Matrigel mix and incubated
at 37°C for polymerization after which DMEM with 10%
FCS and pen/strep supplements was added. The extent
of outgrowth was followed for 5-6 days, and media were
changed to 0% FCS conditions 24-48 h prior to harvest.
The experiments were repeated at least six separate
experiments. A neutralizing IL-6 antibody (R&D systems
#MAB2061) was added to co-cultures at a concentration
of 1 μg/ml. Pure IL-6 (Sigma, I-1394) in concentrations
of 20-50 ng/ml was added to mono-cultures of cancer
cells. Experiments were repeated four times.
Western blot analysis
Proteins were detected using a standard Western blot
procedure after separation by SDS-polyacrylamide elec-
trophoresis. Primary antibodies were incubated ON
according to the suppliers’ instructions: MMP-2 (Neo-
Marker Ab-2, 1:600 dilution), MMP-9 (NeoMarker
clone Ab-5, 1:400 dilution), and affinity purified rabbit
anti-S100A4 [23] (1:2000 dilution). HRP-conjugated rab-
bit anti-mouse or goat anti-rabbit antibodies (DAKO
diluted at 1:2000) and ECL-plus chemiluminescent sub-
strate (Amersham) were used for visualisation.
MMP detection by zymography
Zymography gels were produced from standard 12%
SDS-acrylamide gels containing gelatine or b-casein pro-
tein at a concentration of 1.2 mg/ml. The gels were pre-
run before loading of serum-free CM and run overnight
at 4°C at 50 V. Gels were briefly washed and incubated
at 37°C overnight for gel degradation (washing buffers:
2×3 0m i nw i t h5 0m MT r i s - H C lp H7 . 5 ,2 . 5 %T r i t o n
X-100 and 2 × 10 min in 50 mM Tris-HCl pH 7.5.
Incubation buffer: 50 mM Tris-HCl Ph 7.5, 0.15 M
NaCl, 10 mM CaCl2, 0.1% Triton X-100, 0.02% NaN3).
Gels were stained in Coomassie brilliant blue R-250
solution and subsequently destained in 10% acetic acid.
An LAS-1000 analyser and the MultiGauge software
from Fuji Film were used to process the images.
Cytokine detection using pre-probed membranes
A standard ratio of the volume of media to the number
of cells was used to produce CM in both 2D and 3D
culture experiments enabling us to compare them for
cytokine production.
Membrane-based cytokine arrays from RayBiotech
(C series 1000, detecting 120 and 96 different human
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kines, respectively) were used to analyse CM from the
3D model and mouse TIFs. The protocol supplied by
the manufacturer was followed with slight modifications.
Membranes were blocked for 30 min with protein-free
blocking buffer (ThermoScientific), and 1 ml sample
was added per membrane and incubated overnight at
4°C. Biotin-conjugated secondary antibodies and HRP-
conjugated streptavidin supplied in the kit were both
diluted in the protein-free blocking buffer and incubated
with membranes for 2 h at room temperature before
detection using Amersham ECL™ Advance (Amersham).
Spot intensities were quantified by Image Quant TL
software by normalization to the background and posi-
tive controls.
Enzyme-linked immunosorbent assay (ELISA)
Sandwich ELISAs specific for murine S100A4 were per-
formed according to the assay previously described by
Ambartsumian et al., 2001 [25] to measure the concen-
tration of S100A4 protein in mouse TIFs.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism statistical software. Student’s t-test was used for
evaluation of fibroblast length measurements, tumour
cell scattering and differences in protein expression.
Immunohistochemical staining of PgR was analysed by
Mann-Whitney t-test in the GraphPad Prism software.
Results
Soluble factors promote morphological changes in cancer
cells and fibroblasts
To study the effect of fibroblasts on breast cancer cells,
we co-cultured human mammary (HMF3s) or foreskin-
derived (BJ) fibroblast cell lines with two variants of the
oestrogen-dependent breast cancer cell line, MCF7 and
its derivative MCF7S1. Alternatively we cultivated these
cells in the CM from tumour cells and fibroblasts
respectively. Exposure of both fibroblast cell lines to
CM conditioned for 48 h by tumour cells induced sig-
nificant cell elongation (Fig. 1A). Both cancer cell lines
produced factors that stimulate elongation of fibroblasts,
but the MCF7S1 cells exhibited a more pronounced
effect. Calculation of the increase in cell length showed
that MCF7S1 CM induced a 49.3% and 55.8% increase
in cell length of BJ and HMF3s fibroblasts respectively,
whereas CM from MCF7 cells induced elongation by
42.0% (BJ) and 47.7% (HMF3s) respectively (Fig. 1B).
A similar elongating effect was observed when fibro-
blasts were co-cultured with tumour cells (Fig. 1C,
lower panel). Elongation of HMF3s fibroblasts was
accompanied by increased S100A4 expression, which is
known to be expressed in activated fibroblasts [23]
(Fig. 1C). Western blot analysis of cell lysates obtained
after treatment of cells with CM from cancer cells, as
well as from co-culturing of fibroblasts with cancer
cells, confirmed this observation (Fig. 1D).
Conversely, exposure of tumour cells to CM from
fibroblasts stimulated scattering of the cells which other-
wise grew in characteristic clusters (Fig. 2A, left). The
arrows in Fig. 2A show examples of highly scattered
cells detached from clusters and with protrusions on the
cell surface. Calculation of the proportion of scattered
cells showed that cancer cells were more responsive to
HMF3s CM (Fig. 2B) compared to both BJ CM and
DMEM growth media. These results suggest that ortho-
topic factors from the mammary fibroblasts affect breast
cancer cells differently than those derived from skin.
Fig. 2C shows cell-specific staining of HMF3s fibroblasts
and MCF7S1 cancer cells against vimentin and cytokera-
tins, respectively. These markers are used to distinguish
cell types in co-cultures (Fig. 2C, right panel) showing
fibroblast elongation and cancer cell scattering com-
pared with the mono-cultures (Fig. 2C, two images in
left panel). Cancer cells reorganise into clusters sepa-
rated by streaks of fibroblasts when the co-cultures
become denser (Fig. 2C, lower right panel). Immuno-
fluorescent staining demonstrated that morphological
changes of tumour cells were accompanied by the
decrease of E-cadherin, a hallmark of the epithelial-
mesenchymal transition (EMT) [26] (Fig. 2D). The data
indicate that soluble factors produced by fibroblasts
induce an EMT-like state in cancer cells. Conversely,
factors produced by cancer cells induce morphological
changes in fibroblasts.
Co-culturing fibroblasts and breast cancer cells in 3D
Matrigel stimulates invasion of cancer cells
To investigate whether soluble factors produced by
f i b r o b l a s t sa r ea b l et oi n d u c ec h a n g e si nt u m o u rc e l l s ,
we studied the behaviour of tumour cells and fibroblasts
grown in 3D Matrigel as a support matrix without direct
contact between the two cell types. This was achieved
by generating individual fibroblast and tumour cell
aggregates which were placed into a thick Matrigel layer
separate from each other (at a distance of 0.5-2 mm).
MCF7S1 and HMF3s cells exhibit a stronger mutual
response when grown under conventional 2D culturing
conditions; therefore, we chose these two cell lines for
further analysis. The MDA-MB-231 and ZR-75-1 cell
lines were also tested in the 3D Matrigel model and
gave similar results (data not shown). Neither HMF3s
nor MCF7S1 cell aggregates showed any signs of inva-
sive growth when grown in mono-cultures (Fig. 3A and
3B). In contrast, co-cultures of MCF7S1 and HMF3s
cells demonstrated clear signs of invasive growth into
the Matrigel (Fig. 3D). In most cases, we observed a
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CM also stimulated MCF7S1 cells to invade the gel,
which again confirms the importance of secreted factors
(Fig. 3C). Co-culture of fibroblasts with MCF7S1 cells
also led to expression of S100A4 at the leading edge of
the fibroblast aggregate (Fig. 3E). This observation was
confirmed by Western blot analysis of cell lysates
obtained from 3D cultures (Fig. 3F), where a 2-fold
upregulation of S100A4 was observed in 3D co-cultures
compared to fibroblasts in mono-cultures (green bars in
Fig. 3G). MCF7S1 cells did not express the S100A4
protein.
3D culturing stimulates secretion of cytokines
The ability of fibroblast CM to stimulate the invasion
of tumour cells into the 3D matrix indicated that
secreted factors produced by these cells in response
t ot h e3 Dc u l t u r ec o n d i t i o n sm a yb es u f f i c i e n tt o
Figure 1 Characterisation of fibroblasts and the effect of conditioned media from cancer cells. (A) Phase contrast images of BJ and
HMF3s fibroblasts treated with cancer cell CM in 2D growth conditions. Arrows indicate markedly elongated cells. Scale bars = 100 μm. (B) The
length of fibroblasts in normal growth conditions and when stimulated with cancer cell CM (*** p < 0,0001 by Student’s t-test). (C) Upregulation
of S100A4 expression (green) in HMF3s fibroblasts in response to treatment with cancer cell CM or in co-culture with MCF7S1 tumour cells.
Vimentin (red) was used as a fibroblast-specific marker. Scale bars = 50 μm. (D) Western blot analysis of cell lysates showing increased S100A4
expression in HMF3s cells in response to co-culturing with tumour cells. A-tubulin was used as a loading control. (E) Quantification of the blot
shown in Figure 1D indicating the relative levels of both a-tubulin and S100A4.
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Therefore, we analysed a range of cytokines produced
by tumour cells and fibroblasts grown in different
culture conditions (Fig. 4A). The cytokine protein
microarray, which is able to detect 120 different cyto-
kines, showed that mono-cultures of tumour cells and
fibroblasts are induced to produce increased amounts
of cytokines when cultured in 3D Matrigel compared
with traditional 2D conditions (Fig. 4A, numbered
cytokines in 3D mono cultures). This was especially
clear with HMF3s fibroblasts, in which upregulation
of cytokines, such as granulocyte chemotactic peptide
(GCP)-2, interleukin (IL)-6, IL-8, tissue inhibitor of
metalloproteinases (TIMP), growth-related oncogene
(GRO), and monocyte chemoattractant protein
(MCP)-1, was documented. MCF7S1 cells upregulated
the production of MCP-1, TIMP1, epithelial neutro-
phil activating protein (ENA)-78, and IL-6R and
downregulated stroma-derived factor (SDF)-1 and
macrophage-stimulating protein (MSP)-a in 3D
growth. Co-culturing of tumour cells and fibroblasts
in 3D conditions did not result in the appearance of
new cytokines; rather, the amounts of certain cyto-
kines already upregulated in 3D mono-cultures, such
as GCP-2, IL-6, amphiregulin, GRO/GRO-a,I L 8 ,a n d
MSP-a, were further increased (Fig. 4B). Additional
data on differential expression of cytokines is shown
in the Additional file 1.
Figure 2 Characterisation of cancer cells and the effect of conditioned media from fibroblasts. (A) Phase contrast images of MCF7 and
MCF7S1 cells treated with fibroblast CM in 2D growth conditions. Arrows indicate scattered cancer cells. Scale bars = 100 μm. (B) Percentage of
cancer cells scattered in normal growth conditions and in response to fibroblast CM (** p = 0,0006, * p = 0,0225 by Student’s t-test). (C)
Elongation of HMF3s fibroblasts (arrows) and scattering of MCF7S1 cells in sparse co-culture using vimentin (red) and cytokeratin (green) as cell-
specific markers. Mono-cultures of both cell lines were used as controls. In dense co-culture, fibroblasts shorten and tumour cells are less
scattered. Scale bars = 100 μm. (D) Downregulation of E-cadherin expression (red) in MCF7S1 cells in response to treatment with fibroblast CM.
Oestrogen receptor (ER) (green) was used as a marker for cancer cells. Scale bars = 50 μm.
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of invasion we chose IL-6 because of its well known
association to tumour progression [27]. IL-6 was added
to tumour cells in 3D cultures but we failed to observe
any stimulation of tumour cell invasion (Fig. 4E). In
contrast to that, addition of a neutralizing anti-IL-6 anti-
body completely abolished the stimulation of tumour
cell invasion induced by fibroblasts in co-cultures. This
indicates that IL-6 is essential but not sufficient alone to
stimulate fibroblast induced invasion of tumour cells.
The IL-6 antibody had no effect on invasion of fibro-
blasts in the co-culture (data not shown).
Although the shift from 2D to 3D growth conditions
of fibroblasts and tumour cells led to a dramatic
increase in cytokine production, such a change did not
result in the invasive behaviour of these cells in mono-
culture, whereas co-culturing of these cells markedly sti-
mulated invasion of both cell types.
3D co-cultures induce MMP2 production
One of the functions of stroma fibroblasts is to produce
ECM-degrading enzymes, thereby stimulating cancer cell
invasion [28]. Consequently, we hypothesized that the
invasive growth we observed in 3D co-cultures could be
Figure 3 Invasion of fibroblasts and cancer cells in 3D culturing conditions. (A) Phase contrast images of HMF3s fibroblasts grown in
Matrigel in mono-culture. Notice sparse outgrowth of HMF3s cells. Scale bar = 300 μm. (B) Phase contrast images of MCF7S1 tumour cells
grown in Matrigel in mono-culture. Notice absence of invasion in MCF7S1 cancer cells. Scale bar = 500 μm. (C) Invasion of MCF7S1 cancer cells
in response to treatment with fibroblast CM. Notice pronounced invasion of cancer cells. Scale bar = 500 μm. (D) Mutual invasion of HMF3s
fibroblasts [F] and MCF7S1 cancer cells [C] co-cultured in 3D Matrigel. Inset shows details of the invasive front. Scale bars = 500 and 100 μm,
respectively. (E) Immunohistochemical detection of S100A4 in the invasive front of HMF3s fibroblasts grown in co-culture with MCF7S1 cells.
Arrows point to invading cells. Scale bar = 100 μm. (F) Western blot analysis of cell lysates from 3D cultures showing increased S100A4
expression co-cultures. a-tubulin was used as a loading control. Note that the expected amount of a-tubulin in lane 3 is equal to the sum of
lane 1 and 2. (G) Quantification of the blot shown in Figure 3F with tubulin adjusted to the cell amounts in each lane. The co-culture (3)
represents 100%.
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The CM obtained from 3D co-cultures was therefore
analysed for the presence of protease activity by gelatine
zymography. CM from MCF7S1 mono-cultures did not
contain any detectable proteolytic activity, whereas CM
from HMF3s mono-cultures exhibited gelatinolytic activ-
i t yt om a t c ht h eM M P - 2s t a n d a r do f7 2k D a( F i g .4 C ) .
Casein-based zymographies were also performed but
g e n e r a l l ys h o w e do n l yv e r yl i t t l ea c t i v i t y( d a t an o t
shown). Co-cultured cells revealed intensification of the
72 kDa bands as well as the appearance of lower molecu-
lar weight bands (Fig. 4B). We propose that these lower
molecular weight bands correspond to the active form of
MMP2. To verify the upregulation of MMP-2, we per-
formed Western blot analysis of CM from 3D mono- and
co-cultures with MMP-2-specific antibodies, confirming
MMP-2 as the activated protease (Fig. 4D). Gelatine
zymography was also performed with CM from mono-
and co-cultures of HMF3s and MCF7S1 cells grown in
2D conditions. Although CM from HMF3s cells in 2D
contained MMP-2 protease activity, it was only slightly
upregulated upon co-culturing with MCF7S1 cells com-
pared to the 3D co-culture conditions, and no additional
bands appeared in 2D (data not shown).
Fibroblasts stimulate tumour growth in mouse xenografts
via activation of mouse stroma
Our data demonstrated that factors produced by fibro-
blasts stimulated invasion of MCF7S1 tumour cells in
3D Matrigel. We therefore proposed that fibroblasts
m a yb ea b l et oa f f e c tM C F 7 S 1t u m o u rg r o w t hi na n
orthotopic mouse model. MCF7S1 cells grafted into
Figure 4 Cytokine microarray and zymography analysis of CM from 2D and 3D Matrigel model. (A) Comparison of cytokine microarray
membranes from different growth conditions of HMF3s and MCF7S1 cells. The cytokines altered in 3D culturing conditions in HMF3s or MCF7S1
cells are numbered and correspond to: 1, GCP-2; 2, IL-6; 3, MCP-1; 4, MCP-3; 5, Amphiregulin; 6, Fas/TNFRSF6; 7, FGF-4; 8, GCSF; 9, GRO; 10, GRO-
a; 11, IL-8; 12, MSP-a; 13: TIMP-1, 14, TIMP-2; 15, uPAR (urokinase plasminogen activator receptor); 16, VEGF (vascular-endothelial growth factor);
17, SDF-1; 18, ENA-78; 19, IL-6R; 20, sTNF-RI. (B) Significant increase in cytokine levels in CM from 3D Matrigel co-culture of HMF3s and MCF7S1
cancer cells compared with 3D mono-cultures (upregulated cytokines are marked on the membranes from co-culture). (C) Gelatine zymography
showing upregulation of MMP-2 activity. The lower panel shows quantification of band intensities. (D) Western blot analysis of CM from 3D
Matrigel co-culture of HMF3s and MCF7S1 cell aggregates showing marked upregulation of MMP-2. The lower panel shows quantification of
band intensities of both pro- and active-MMP2. (E) 3D invasion assay stimulated with IL-6 in MCF7S1 monocultures and inhibited with IL-6-
specific inhibitor in MCF7S1 + HMF3s co-cultures. A co-culture without the inhibitor is shown for reference.
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gen-independent growth of these cells is an indicator of
their progressed state [30]. To test whether the presence
of fibroblasts could render MCF7S1 cells ability to grow
in the absence of oestrogen, MSF7S1 cells in combina-
tion with HMF3s were orthotopically implanted into
mammary fat pads of Balb/c nu/nu mice with and with-
out oestrogen supplementation.
The dynamics of tumour growth were monitored for
100 days. We were able to document the steady growth
of tumours when MCF7S1 cells were implanted together
with HMF3s fibroblasts, both with and without oestro-
gen supplementation (Fig. 5A). In the presence of oes-
trogen, HMF3s fibroblasts provided MCF7S1 cells with
additional growth capabilities by the acceleration of
tumour growth initiation as compared to the tumours
developed without HMF3s cells (Fig. 5A). Fig. 5B shows
that the average sizes of tumours developed in mice
injected with MCF7S1 + HMF3s cells were similar at
the time of termination of the experiment independent
of the presence of supplemented oestrogen. At post
mortem analysis, tissue sections obtained from the
regions with palpable tumour-like mass detected in the
control group injected with MSF7S1 cells without estro-
gen supplementation (Fig 5B) revealed absence of
tumour cells.
We were not able to detect metastasis in the lungs of
mice from any experimental groups.
We next performed immunohistochemical staining of
tumour sections with antibodies against ER and PgR
( F i g .5 C ) .E Re x p r e s s i o nw a ss i m i l a ri nt h et u m o u rs e c -
tions obtained from mice from all experimental groups.
In contrast, tumours that developed in mice implanted
with MCF7S1 + HMF3s cells without oestrogen
showed significant downregulation of PgR, a well-
known downstream target of ER [31] (Fig. 5C and 5D).
Downregulation of PgR expression therefore indicated
that at the time of sacrifice, the levels of oestrogen,
endogenous or produced by the grafted cells, at the
site of implantation were below the concentration
required to induce PgR expression. We therefore
assumed that the growth of MSF7S1 cells co-injected
with HMF3s fibroblasts was supported by the produc-
tion of other factors rather than increased oestrogen
production in the mouse.
We attempted to detect the presence of HMF3s
human fibroblasts in MCF7S1 + HMF3s tumours.
Immunostaining of tumour sections with human fibro-
blast-specific prolyl-4-hydroxylase antibodies [32] did
not reveal the presence of any positive cells (Fig. 6B).
HMF3s fibroblasts stained positive for prolyl-4-hydroxy-
lase in cell cultures (Fig. 6C, left) and the marker also
detects fibroblasts in human breast tumour tissue (Fig.
6C, right).
Immunostaining of tumour sections with anti-S100A4
polyclonal antibodies that recognise both human and
murine S100A4 revealed the presence of numerous
S100A4-positive cells in the stroma. Some of these cells
had an elongated morphology (notice green arrows in
Fig. 6A and yellow arrows in Fig. 6B), and we presume
that these were mouse fibroblasts replacing human cells
in the course of tumour development. S100A4-positive
cells were increased in MCF7S1 + HMF3s tumours
compared with MCF7S1 tumours (Fig. 6A). Other
S100A4-positive cells had morphologically rounded fea-
tures and were likely to be immune cells (red arrows in
Fig. 6A).
Immunohistochemical staining with mouse macro-
phage-specific F4/80 antibodies showed that mouse
macrophages were much more abundant in MCF7S1 +
HMF3s tumours compared with MCF7S1 tumours (Fig.
6A, lower panel), suggesting that augmented develop-
ment of mouse-derived stroma produces soluble factors
that support oestrogen-independent growth of MCF7S1
tumour cells.
Immunohistochemical staining of tumour sections for
the components of ECM; fibronectin and laminin,
showed that in contrast to MCF7S1 tumours, MCF7S1
+ HMF3s tumours contained an extremely well-devel-
oped ECM (Fig. 6A).
All this indicates that the tumour stroma of MCF7S1
+ HMF3s tumours was much more developed.
Co-injection of human fibroblasts stimulates the
production of murine S100A4 and MMP2
The metastasis-related protein S100A4, which is known
to be produced by stroma cells, has been linked to both
angiogenesis and the invasion of tumour cells as an
extracellular factor [25,33]. Therefore, we investigated
whether increased numbers of observed S100A4-positive
stroma cells correlated with its secretion by analysing
TIFs using an S100A4 mouse-specific sandwich ELISA.
Fig. 7A shows an increased concentration of S100A4 in
TIFs from MCF7S1 + HMF3s tumours compared with
MCF7S1 tumours. The murine S100A4 concentration in
TIFs from mice injected with cancer cells alone ranged
from 39.4 to 60.3 ng/ml (mean, 51.5 ± 12.2 ng/ml). TIFs
from MCF7S1 + HMF3s ranged from 60.0 to 241.3 ng/
ml (mean, 161.5 ± 62.0 ng/ml), resulting in a significant
increase in S100A4 release (p = 0.01). The average mur-
ine S100A4 concentration in TIFs from MCF7S1 +
HMF3s tumours was 2.5-3-fold higher than in TIFs
from MCF7S1 tumours. TIFs were also investigated
using a human-specific sandwich ELISA assay, but no
human S100A4 was detected.
We next investigated protease activity present in TIFs
from MCF7S1 and MCF7S1 + HMF3s tumours. Gelatin
zymography revealed several major and minor bands, of
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dards (Fig. 7B, upper panel). Quantification of the inten-
sity of the MMP-2-specific bands showed increased
activity of MMP-2 in TIFs isolated from MCF7S1 +
HMF3s tumours (Fig. 7B, lower panel). MMP-2 upregu-
lation was confirmed by Western blot analysis with
MMP-2-specific antibodies (Fig. 7C). MMP-9 activity in
co-injection xenografts was not found to be different
from mono-injections.
We observed an enhancement of cytokine release in
the 3D model in co-culture conditions, and we com-
pared this cytokine release in tumours to determine
whether the fibroblasts were also able to stimulate
cytokine production in vivo. Human-specific cytokine
microarray analysis revealed that TIFs from MCF7S1
or MCF7S1 + HMF3s tumours generally contained low
levels of human cytokines compared with the 3D
model (Fig. 7D). TIFs from MCF7S1 + HMF3s
tumours contained slightly lower levels of IL-8 and
basic fibroblast growth factor (bFGF) and increased
levels of TIMP-1 (cytokine numbers 1, 2, and 3,
respectively).
In contrast, a similar analysis performed using a
mouse-specific cytokine microarray revealed that TIFs
from MCF7S1 + HMF3s xenografts contained increased
amounts of numerous mouse-specific cytokines, in parti-
cular resistin, IL-6, and MMP-2 (Fig. 7E, cytokine no. 6,
4, and 9, respectively). The level of pro-MMP-9 was
lowered in TIFs from co-injection xenografts (Fig. 7E,
cytokine no. 5).
We assume, therefore, that stimulation of MCF7S1
cell growth triggered by human fibroblasts in an ortho-
topic mouse model is dependent on the pronounced
development of host-derived stroma that supply tumour
growth by the mouse-derived cytokines, S100A4 and
MMPs.
Figure 5 HMF3s fibroblasts stimulate tumour growth of MCF7S1 cells in xenograft mouse model. (A) Dynamics of tumour growth in
mice implanted with MCF7S1 + HMF3s cells with and without oestrogen supplementation. (B) Tumour incidence and average tumour sizes in
different experimental groups. (C) Immunohistochemical staining of tumour sections with ER- and PgR-specific antibodies. The mice were
injected with (a) MCF7S1 cells + oestrogen, (b) MCFS7S1 + HMF3s cells +oestrogen. (c) MCFS7S1 + HMF3s cells without oestrogen. Scale bars =
50 μm. Notice downregulation of PgR expression in the tumour sections without hormone supplementation. PgR expression is almost absent in
xenografts without the hormone supplementation. (D) Quantification of PgR-positive cells in tumour xenografts with and without hormone
supplementation (*** p = 0,0006).
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Page 10 of 16Figure 6 Immunohistochemical analysis of tumour xenografts. (A) Immunohistochemical staining of tumour xenografts against fibronectin,
laminin, S100A4, and F4/80. Green arrows indicate elongated S100A4-positive cells, and red arrows indicate smaller rounded cells. Scale bars =
100 μm. (B) Double-immunostaining of tumour sections from HMF3s + MCF7S1 co-injections detecting S100A4 (green) and human prolyl-4-
hydroxylase (red). Yellow arrows indicate elongated cells expressing S100A4 but not prolyl-4-hydroxylase. Scale bar = 100 μm. (C) Positive control
for prolyl-4-hydroxylase staining on cell cultures of the HMF3s fibroblast (red = prolyl-4-hydr, S100A4 = green, scale bar = 200 μm) and a human
tumour sample (scale bar = 50 μm).
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Despite the increasing appreciation of the importance of
tumour-stroma interactions in the progression of cancer,
little is known about the factors regulating the crosstalk
between stroma and neoplastic cells. Fibroblasts repre-
sent the major cellular component of cancer-associated
stroma [34,35]. Although their role in accelerating can-
cer growth and possibly causing malignant conversion
has been demonstrated, the molecular factors regulating
these processes remain largely unknown [36].
A number of studies have suggested that stroma-asso-
ciated fibroblasts exert their stimulatory effect by under-
going genetic changes [37,38]. It has been shown that
genetic alteration in the stroma is a more accurate
predictor of prognosis than w h o l et i s s u es i g n a t u r e s
[39,40]. However, other mechanisms operating at the
level of (de)regulation of gene expression may be more
important during the early stages of the disease when
rapid and massive changes are evoked in the stroma.
We attempted to analyse the reciprocal changes that
occur in tumour cells and fibroblasts by modelling
tumour-stroma interactions, with a main focus on soluble
factors able to stimulate tumour progression and produced
by human mammary fibroblast. We compared three
model systems in which MCF7S1 breast cancer cells and
HMF3s human mammary fibroblasts were co-cultured in
2D conditions and 3D Matrigel and orthotopically injected
in vivo into the mouse mammary fat pad.
Figure 7 Analysis of TIFs from tumour xenograft tumours. (A) Concentration of murine S100A4 in TIFs measured by mouse-specific
sandwich ELISA (** p = 0,001). (B) Gelatine zymography showing upregulation of MMP-2 activity in TIFs obtained from tumours co-injected with
HMF3s and MCF7S1 cells. The lower panel shows quantification of the activity of MMP-2 and MMP-9. Notice that only MMP-2 activity is
significantly upregulated (p = 0.001). (C) Western blot analysis of TIFs from tumours co-injected with HMF3s and MCF7S1 cells showing
upregulation of MMP-2 expression. The lower panel shows quantification of band intensities with a significant increase (p = 0.029). (D)
Comparison of human-specific cytokine profiles of TIFs from mono- and co-injection xenografts. Cytokines altered from mono- to co-injections
are numbered 1 to 3 (1, bFGF↓; 2, IL-8↓; 3, TIMP-1↑). (D) Comparison of mouse-specific cytokine profiles of TIFs from mono- and co-injection
xenografts. Cytokines altered from mono- to co-injections are numbered 4 to 9 (4, IL-6↑; 5, pro-MMP9↓; 6, Resistin↑; 7, Thymus CK-1↓; 8, TIMP-2↑;
9, MMP2↑).
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tering of both MCF7 and MCF7S1 cells with subsequent
downregulation of E-cadherin. Loss of E-cadherin
expression has been correlated with in vitro invasiveness
and in vivo tumour progression [41]. Downregulation of
E-cadherin in our system was correlated with changes in
tumour cell morphology but not with changes of vimen-
tin or a-smooth muscle actin expression (data not
shown). EMT is a complex multistage process that
includes morphological changes accompanied by modu-
lation of the expression of numerous proteins, in parti-
cular cytoskeletal and adhesion molecules [42]. We
therefore propose that at short term co-culturing of
tumour cells with fibroblasts we observe early steps of
EMT-like changes that can eventually lead to appear-
ance of a mesenchymal phenotype [43]. Simultaneously,
CM from cancer cells upregulated S100A4 expression,
which is known to be overexpressed in activated fibro-
blasts and HMF3s fibroblasts, and stimulated substantial
elongation of fibroblasts. These observations point to
the role of soluble factors produced by tumour cells and
fibroblasts in stimulation of morphological changes in
both cell types.
Several groups have demonstrated that normal fibro-
blasts exert an inhibitory effect on tumour cells, whereas
the tumour-associated fibroblasts stimulate tumour cell
growth and proliferation [18,44]. Immortalized fibroblast
cell lines used in this study express smooth-musle actin
and S100A4, pointing to their activated state [45].
To analyse the input of soluble factors on the growth
of tumour cells and fibroblasts in 3D culture conditions
we cultivated MCF7S1 and HMF3s cell aggregates in 3D
Matrigel in the absence of direct contact between cells.
Both cell types were induced to invade the ECM when
grown in co-culture, but not in mono-culture. Again, we
obtained evidence demonstrating that the presence of
soluble factors was sufficient to stimulate invasion with-
out the need for direct cell-cell contact.
3D culturing conditions led to a dramatic increase in
release of a number of cytokines. The most prominent
cytokines that have also been shown to be linked with
cancer development were IL-6 [27,46], IL-8 (CXCL8)
[47,48], GRO/GRO-a (CXCL1) [49,50], GCP-2 (CXCL6)
[51], and TIMP-1 [52,53]. These cytokines were virtually
not detectable in CM from 2D growth and were highly
upregulated in CM from 3D Matrigel mono-cultures
with HMF3s cells.
Co-culturing of fibroblasts with tumour cells in 3D
Matrigel led to further upregulation of many of these
cytokines. This was especially pronounced with GCP-2,
IL-6, IL-8, GRO/GRO-a,a n dM S P - a. Interestingly,
increased expression of the identified cytokines in the
tumour microenvironment has been associated with
poor prognosis in many cancer types [54,55].
Invasion of tumour cells by addition of a single cyto-
kine (IL-6) was not enough to trigger the complex pro-
cess of tumour cell invasion. Whereas blocking of IL-6
by a neutralising antibody showed that increased
amounts of this cytokine was necessary for tumour cell
invasion, indicating that a complex cytokine network is
needed for stimulation of this process.
In addition to cytokine activation 3D co-culturing also
stimulated increased production of matrix metalloprotei-
nases, in particular MMP2. MMP-2 is known to be
induced in tumour stroma cells, mainly by tumour-asso-
ciated fibroblasts in response to the presence of tumour
cells or tumour-produced factors [56,57].
Similar to the 2D co-culture conditions expression of
S100A4 in HMF3s fibroblasts was also up-regulated in
3D co-culture. S100A4 is a stromal derived factor [45]
capable of stimulating the production of several MMPs
[58,59] and induce angiogenesis by attraction of
endothelial cells [25]. Furthermore, T-cells are attracted
to the tumour milieu by S100A4 and thereby inducing
an inflammatory response in the tumour microenviron-
ment through elevation of T-cell specific cytokines [60].
Altogether these observations indicate that a 3D co-
culturing model leads to an increase in the production
of a number of molecules that are capable of stimulating
aggressive invasive behaviour of cancer cells. In the 3D
co-culture model used in the present work, the invasive
phenotype was induced only by soluble factors, because
cell aggregates were co-cultured in 3D Matrigel in the
absence of direct contact. This contrasts with other 3D
co-culture models that have been developed and used to
study reciprocal direct cellular interactions between
tumour and stroma cells [44,61,62].
We suggest that the 3D co-culture model used in the
present study could be useful for studying soluble fac-
tors produced in the tumour microenvironment by cer-
tain combinations of tumour and stroma cells.
Factors that were up-regulated in 3D co-cultures of
breast cancer cells and fibroblasts have been shown to
be involved in malignant progression of breast cancer. It
has been shown that elevated serum levels of IL-6 and
MMP-2 in breast cancer patients correlates with the
s t a g ea n dt h es e v e r i t yo ft h ed i s e a s e[ 6 3 , 6 4 ] .M M P - 2i s
expressed in the early stages of breast cancer and is
believed to contribute to the first events leading to
tumour formation because of its ability to degrade the
basement membrane [65].
The observed increase in S100A4 in our xenograft
model is of great interest since it has been shown in
several studies how overexpression of this protein is cor-
related with a poor prognostic outcome in breast cancer
patients [66,67].
To assess the stimulatory effect of activated fibroblasts
on tumour cells in in vivo conditions we orthotopically
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fibroblasts into the immunodeficient mice with and
without oestrogen supplementation. Growth of ER-posi-
tive MCF7S1 cells is oestrogen-dependent, both in vitro
and in vivo, in mouse xenograft models [29].
Orthotopic injection of these cells with HMF3s human
fibroblasts into the mammary fat pad of immunodeficient
mice led to the formation of tumours in the absence of
oestrogen supplementation which indicated that MSF7S1
cells acquired a more aggressive phenotype.
Tumours were characterized by extensive development
of stroma. Our analysis revealed that the stroma formed
in these tumours did not contain human-specific fibro-
blasts. Moreover, we were not able to detect an increase
in the production of human-specific cytokines released
in TIFs of MCF7S1 + HMF3s tumours.
Mouse-specific cytokine antibody array analysis of
MSF7S1 + HMF3s tumours showed that they contain
increased numbers of overexpressed cytokines compared
with TIFs generated from MCF7S1 tumours. The most
prominent increase was observed in the levels of resis-
tin, which has been identified as a biomarker of bladder
cancer [68] and is up-regulated in women with polycys-
tic ovarian syndrome [69] but has not been linked
directly with mammary cancer.
MMP-2 was upregulated in co-injection tumours,
demonstrated by zymography, Western blot, and cyto-
kine array analysis of TIF. The upregulation of murine
cytokines correlated with increased infiltration of mur-
ine cells into human xenografts.
The expression of S100A4 has been previously shown
to be stimulated by growth factors [70].
We documented an increase in the secretion of mur-
ine, but not human S100A4 into the MCF7S1 + HMF3s
tumour microenvironment. The S100A4 protein is pro-
duced by murine fibroblasts and macrophages [71,72]
which were found in larger numbers in tumour xeno-
grafts from co-injections. It has been shown that
S100A4 in xenograft injection experiments can render
MCF7 cells oestrogen independent [73]. We propose
that the observed increase in S100A4 is one of the fac-
tors responsible for the oestrogen independent growth
of MCF7S1 + HMF3s xenografts.
It is possible that another cytokine upregulated in the
MCF7S1 + HMF3s tumours alone or in combination
could trigger hormone-independent growth of MCF7S1
cells. It has been shown previously that cytokines, such
as VEGF, FGF, TGF-b and BMP could stimulate hor-
mone-independent growth of MCF7 cells in vivo [74-78].
Human fibroblasts have been shown previously to sti-
mulate tumour progression in orthotopic mouse models
[44,79], and human stroma cells are shown to be
replaced by mouse host-derived stroma cells in a similar
orthotopic transplantation model [80].
We therefore speculate that human fibroblasts per-
form the initial stimulation of MCF7S1 tumour cell
growth, possibly by producing increased oestrogen con-
centrations [81] and by attracting murine stroma cells
to infiltrate the growing tumour and create a microen-
vironment that support hormone-independent growth of
MCF7S1 tumour cells.
Conclusion
Co-culturing of human tumour cells and fibroblasts in
3D Matrigel in the absence of direct cell contacts stimu-
lates the production of a complex network of molecules
that induce invasion of both cell types generating a
more aggressive phenotype. Moreover, the mouse model
experiments suggest that the murine host-derived cyto-
kine network replaces human-derived cytokines in sti-
mulation of hormone-independent growth of MCF7S1
breast cancer cells.
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Additional file 1: Complete table of quantification of cytokine
detection arrays. Quantification of spot intensities from RayBiotech
cytokine detection arrays including the calculated fold increase and p-
values for each cytokine. The cytokines marked in red are significantly
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are emphasised in Fig. 4B.
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